Utility of p53 immunohistochemistry as a surrogate for sequencing in myeloid neoplasms: A tale of caution
American Journal of Hematology · 2024
DOI: 10.1002/ajh.26970 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Karen A Nahmod und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
The authors declare no conflicts of interest. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Karen A Nahmod, Koji Sasaki, Chi Young Ok, Sanam Loghavi
Zitieren
APA
Nahmod, K. A., Sasaki, K., Ok, C. Y., & Loghavi, S. (2024). Utility of p53 immunohistochemistry as a surrogate for sequencing in myeloid neoplasms: A tale of caution. American Journal of Hematology. https://doi.org/10.1002/ajh.26970
Vancouver
Nahmod KA, Sasaki K, Ok CY, Loghavi S. Utility of p53 immunohistochemistry as a surrogate for sequencing in myeloid neoplasms: A tale of caution. American Journal of Hematology. 2024. doi:10.1002/ajh.26970
BibTeX
@article{Nahmod2024,
author = {Nahmod, Karen A and Sasaki, Koji and Ok, Chi Young and Loghavi, Sanam},
title = {Utility of p53 immunohistochemistry as a surrogate for sequencing in myeloid neoplasms: A tale of caution},
journal = {American Journal of Hematology},
year = {2024},
doi = {10.1002/ajh.26970}
}
EUVIMED